TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Inventiva ( (IVA) ).
On November 27, 2025, Inventiva held its Combined Shareholders’ General Meeting where all proposed resolutions were adopted except for the fifth, which was opposed by the Board of Directors. This resolution would have allowed the Board to increase share capital for a company savings plan. The meeting also approved the compensation policy for the CEO, reflecting shareholder support for the company’s strategic direction. The outcomes of the meeting indicate a strong alignment between the shareholders and the management, potentially reinforcing Inventiva’s position in the biopharmaceutical industry.
The most recent analyst rating on (IVA) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its weak financial performance and challenging valuation. The company’s persistent financial difficulties and negative P/E ratio are significant concerns. Technical analysis provides a slightly more neutral perspective, but the lack of clear positive momentum and potential overbought conditions limit upside potential.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs. The company is publicly traded on Euronext Paris and Nasdaq, and is currently conducting a pivotal Phase 3 clinical trial for its novel drug candidate, lanifibranor, targeting MASH.
Average Trading Volume: 229,498
Technical Sentiment Signal: Buy
Current Market Cap: $820.8M
For an in-depth examination of IVA stock, go to TipRanks’ Overview page.